Today the machines that read the whole field — 129 separate signals in all — kept landing on the same hard truth. No psychedelic drug will be moved out of the government's most restricted drug category, Schedule I, in the next twelve months. No new law aimed at freeing these medicines is expected to pass. And the FDA, the agency that decides which drugs Americans can legally take, is not expected to approve any psychedelic within a year. The reasoning is plain: the people who guard the rules still have unanswered safety questions, and they will not rush.
At the same time, the money moved. Compass Pathways, a company testing psilocybin — the active part of magic mushrooms — for depression, rose about 3 percent today. Another firm, MindMed, rose about 2.5 percent. The swarm's honest read is that these small bumps will likely fade within weeks unless real trial results arrive. There is also a warning worth hearing: one prediction, held at 66 percent, says a psilocybin depression trial will report a strong positive result this year. Another, at 65 percent, says surprising or uncomfortable safety findings could show up too. Both can be true.
Beneath all this is one clear pattern. The healing is running ahead of the paperwork. Scientists are learning faster than lawmakers can write rules or regulators can sign off. That gap looks like a delay, but it is actually a sign of life. Real trials are underway right now — for depression, for burnout, even for Parkinson's disease. The reason approval feels far away is not that these medicines fail. It is that the people in charge are being careful, and careful is slow. The highest path here is not a sudden law that changes everything overnight. It is steady, honest evidence stacking up until the science is strong enough that the rules simply have to catch up.
Picture the people waiting inside this gap. A veteran who cannot sleep because the war still plays in his head. A mother whose depression has not lifted in years, who has tried every pill and found no door. A therapist who has watched patients wake up after one careful session and wants to offer that legally, safely, without fear. For them, today's news is not defeat. It is a promise that the work is real and being done right — so that when the door finally opens, it opens for good, not for a moment. The slowness is the sound of something being built to last.
OOTW doesn't sell products. It delivers transmissions — a daily reminder that the intelligence which created us is still creating, still calling us forward.
The medicine is older than the fear. The healing is older than the wound.
97%
No psychedelic drug will get US approval in the next month
The FDA (the US drug regulator) won't approve any psychedelic-based treatment in the next 30 days. This matters because approval would be the green light for doctors to legally prescribe these treatments — and that moment is still a while away.
→ Nothing is changing in psychedelic medicine regulation for at least the next 30 days — it's simply not on the FDA's schedule.
Resolves: 2026-08-20 · USA
REGULATION
the precise call ▾
No FDA approval of any psychedelic therapy within 30 days.. No psychedelic candidate has an active PDUFA target date within the next month, and FDA approvals are preceded by publicly tracked advisory committee meetings and acceptance announcements — none pending. Near-term approval is administratively implausible. || RESOLUTION RULE: YES if, as of 2026-08-20
93%
Federal law on psychedelics won't change in the next three months
The DEA (the US agency that controls which drugs are legal and illegal) won't move any psychedelic out of Schedule I — the most restricted category — in the next 90 days. Rescheduling requires a long chain of government steps, and none of those steps have even started.
→ Changing federal drug law is a slow bureaucratic process, and that process hasn't started — so nothing will change in 90 days.
Resolves: 2026-10-19 · USA
REGULATION
the precise call ▾
No federal rescheduling of any psychedelic out of Schedule I within 3 months.. Consensus of 5 agents (dea_officer, legislator, fda_reviewer, veteran_advocate, neuroscientist), 0 dissenting. DEA rescheduling requires a formal proposed rule, an HHS scientific review, and a public comment period — none of which are in motion in the current docket. The multi-step administrative ti
60%
A recent stock rally in psychedelic companies will likely fade by mid-September
Psychedelic company stocks recently got a boost from general market excitement — not from any specific breakthrough of their own. Without a real concrete milestone like a successful drug trial or a major acquisition, those gains tend to fade. COMPASS Pathways (ticker: CMPS), a leading publicly traded psychedelic company, is being used here as the measuring stick.
→ Without a real breakthrough — like a successful trial result or a big acquisition — the recent excitement around psychedelic stocks will probably cool off by mid-September.
Resolves: 2026-09-15 · Global
MARKET
the precise call ▾
Psychedelic equity sector gains from today will not hold through mid-September absent a hard clinical/M&A catalyst.. Sector-beta rallies driven by sentiment (e.g., Lilly's $3.8B deal) mean-revert without asset-specific catalysts. Using COMPASS Pathways (CMPS) as the named liquid proxy makes this cleanly measurable. || RESOLUTION RULE: YES if COMPASS Pathways (NASDAQ: CMPS) closing price on 2026-09-15 is BELOW its
60%
At least one major psilocybin depression study will show clear positive results this year
Several large clinical trials testing psilocybin (the active compound in magic mushrooms) as a depression treatment are expected to share results before the end of 2026. At least one of them is likely to show that psilocybin worked significantly better than the comparison treatment. This would be a meaningful step toward eventually getting it approved as a medicine.
→ There's a 60% chance that solid scientific proof of psilocybin's power against depression will land before the end of 2026 — and that would be a big deal.
Resolves: 2026-12-31 · Global
RESEARCH
the precise call ▾
At least one Phase 2/3 psilocybin depression trial will report a statistically significant positive primary endpoint by year end.. Multiple active late-stage psilocybin depression programs (e.g., COMPASS COMP360 in TRD) have readouts scheduled in 2026; the consistent cross-site efficacy signal makes at least one positive primary-endpoint report likely before Dec 31. || RESOLUTION RULE: YES if, on or before 2026-12-31, a company